EDURANT
Pronunciation: ril-pi-VIR-een (EE-dur-ant)

What it isNon-nucleoside reverse transcriptase inhibitor; HIV.
Why this oneA small tablet with good tolerability, and it is the oral partner in the long-acting injectable regimen.
What limits itIt fails above a viral load of 100,000 or with low CD4. It needs food and acid, so PPIs are contraindicated.
Animated chart of estimated U.S. prescriptions per year, HIV antiretrovirals (1987–2026). Rilpivirine enters in 2011 (estimated).
Principal riskIt fails at high viral load; PPIs are contraindicated
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityAgent-specific renal, hepatic, hematologic, metabolic and drug-interaction toxicity.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| HIV-1 infection, treatment-naive (with other antiretrovirals) | adult | 25 mg QD with a meal | 25 mg QD with a meal | 25 mg QD (50 mg QD only during rifabutin coadministration) |
| HIV-1 infection, treatment-naive (with other antiretrovirals) | peds ≥2 y, 14 to <20 kg | 12.5 mg QD with a meal (Edurant PED oral suspension) | 12.5 mg QD | 12.5 mg QD |
| HIV-1 infection, treatment-naive (with other antiretrovirals) | peds ≥2 y, 20 to <25 kg | 15 mg QD with a meal (Edurant PED oral suspension) | 15 mg QD | 15 mg QD |
| HIV-1 infection, treatment-naive (with other antiretrovirals) | peds ≥25 kg | 25 mg QD with a meal (25 mg tablet) | 25 mg QD | 25 mg QD |
| Oral lead-in / bridging for Cabenuva (with cabotegravir 30 mg) | adult & adolescent ≥12 y, ≥35 kg | 25 mg QD with a meal x ~1 month (≥28 days) lead-in | 25 mg QD with a meal | 25 mg QD |
Renal Mild-moderate: no adjustment; severe/ESRD: use with caution and increased adverse-effect monitoring (concentrations may rise); unlikely removed by dialysis
Hepatic Mild-moderate (Child-Pugh A/B): no adjustment; severe (C): not studied
Always take with a meal; use in combination with other antiretrovirals
Available strengths
Pregnancy APR data show no difference in overall birth-defect risk vs background; rilpivirine exposures lower during pregnancy — monitor viral load closely
Lactation Present in human milk; risks include HIV transmission, viral resistance, and infant adverse reactions
| Strength | #/mo | generic $/mo | brand $/mo | CostPlus | |
|---|---|---|---|---|---|
| 2.5 mg | tab | 30 qd | — | not offered | |
| 25 mg | tab | 30 qd | — | $1,441.23 | not offered |
Available combined with: cabotegravir / rilpivirine
Generic entry2026
Open Rilpivirine in the interactive console ↗